Literature DB >> 12760852

Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors.

Markus Niewerth1, Donika Kunze, Michael Seibold, Martin Schaller, Hans Christian Korting, Bernhard Hube.   

Abstract

The hydroxypyridone ciclopirox olamine belongs to the antimycotic drugs used for the treatment of superficial mycoses. In contrast to the azoles and other antimycotic drugs, its specific mode of action is only poorly understood. To investigate the mode of action of ciclopirox olamine on fungal viability, pathogenicity, and drug resistance, we examined the expression patterns of 47 Candida albicans genes in cells grown in the presence of a subinhibitory concentration (0.6 micro g/ml) of ciclopirox olamine by reverse transcription-PCR. In addition, we used suppression-subtractive hybridization to further identify genes that are up-regulated in the presence of ciclopirox olamine. The expression of essential genes such as ACT1 was not significantly modified in cells exposed to ciclopirox olamine. Most putative and known virulence genes such as genes encoding secreted proteinases or lipases had no or only moderately reduced expression levels. In contrast, exposure of cells to ciclopirox olamine led to a distinct up- or down-regulation of genes encoding iron permeases or transporters (FTR1, FTR2, FTH1), a copper permease (CCC2), an iron reductase (CFL1), and a siderophore transporter (SIT1); these effects resembled those found under iron-limited conditions. Addition of FeCl(3) to ciclopirox olamine-treated cells reversed the effect of the drug. Addition of the iron chelator bipyridine to the growth medium induced similar patterns of expression of distinct iron-regulated genes (FTR1, FTR2). While serum-induced yeast-to-hyphal phase transition of C. albicans was not affected in ciclopirox olamine-treated cells in the presence of subinhibitory conditions, a dramatic increase in sensitivity to oxidative stress was noted, which may indicate the reduced activities of iron-containing gene products responsible for detoxification. Although the Candida drug resistance genes CDR1 and CDR2 were up-regulated, no change in resistance or increased tolerance could be observed even after an incubation period of 6 months. This was in contrast to control experiments with fluconazole, in which the MICs for cells incubated with this drug had noticeably increased after 2 months. These data support the view that the antifungal activity of ciclopirox olamine may at least be partially caused by iron limitation. Furthermore, neither the expression of certain multiple-drug resistance genes nor other resistance mechanisms caused C. albicans resistance to this drug even after long-term exposure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12760852      PMCID: PMC155814          DOI: 10.1128/AAC.47.6.1805-1817.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  58 in total

1.  Cloning and characterization of a gene (LIP1) which encodes a lipase from the pathogenic yeast Candida albicans.

Authors:  Yue Fu; Ashraf S Ibrahim; William Fonzi; Xiang Zhou; Clarisa F Ramos; Mahmoud A Ghannoum
Journal:  Microbiology (Reading)       Date:  1997-02       Impact factor: 2.777

2.  Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene.

Authors:  Dominique Sanglard; Françoise Ischer; Michel Monod; Jacques Bille
Journal:  Microbiology (Reading)       Date:  1997-02       Impact factor: 2.777

3.  Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries.

Authors:  L Diatchenko; Y F Lau; A P Campbell; A Chenchik; F Moqadam; B Huang; S Lukyanov; K Lukyanov; N Gurskaya; E D Sverdlov; P D Siebert
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

4.  Molecular cloning and characterization of a Candida albicans gene (EFB1) coding for the elongation factor EF-1 beta.

Authors:  V Maneu; A M Cervera; J P Martínez; D Gozalbo
Journal:  FEMS Microbiol Lett       Date:  1996-12-01       Impact factor: 2.742

5.  Ultrastructural investigations of Candida albicans after in vitro treatment with the new fungicidal agent rilopirox.

Authors:  H K Reitze; D R Dannhorn; H Hänel; K A Seitz
Journal:  Mycoses       Date:  1993 Nov-Dec       Impact factor: 4.377

6.  Experimental evidences for a role of subinhibitory concentrations of rilopirox, nystatin and fluconazole on adherence of Candida spp. to vaginal epithelial cells.

Authors:  P C Braga; S Maci; M Dal Sasso; M Bohn
Journal:  Chemotherapy       Date:  1996 Jul-Aug       Impact factor: 2.544

7.  Overexpression of a cloned IMP dehydrogenase gene of Candida albicans confers resistance to the specific inhibitor mycophenolic acid.

Authors:  G A Köhler; T C White; N Agabian
Journal:  J Bacteriol       Date:  1997-04       Impact factor: 3.490

8.  Candida albicans gene encoding resistance to benomyl and methotrexate is a multidrug resistance gene.

Authors:  R Ben-Yaacov; S Knoller; G A Caldwell; J M Becker; Y Koltin
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

9.  Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals.

Authors:  R Prasad; P De Wergifosse; A Goffeau; E Balzi
Journal:  Curr Genet       Date:  1995-03       Impact factor: 3.886

10.  Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters.

Authors:  D Sanglard; K Kuchler; F Ischer; J L Pagani; M Monod; J Bille
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

View more
  51 in total

1.  Fungicidal monoclonal antibody C7 interferes with iron acquisition in Candida albicans.

Authors:  Sonia Brena; Jonathan Cabezas-Olcoz; María D Moragues; Iñigo Fernández de Larrinoa; Angel Domínguez; Guillermo Quindós; José Pontón
Journal:  Antimicrob Agents Chemother       Date:  2011-04-25       Impact factor: 5.191

Review 2.  Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?

Authors:  David Brown
Journal:  Nat Rev Drug Discov       Date:  2015-10-23       Impact factor: 84.694

3.  Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK.

Authors:  Hongyu Zhou; Chaowei Shang; Min Wang; Tao Shen; Lingmei Kong; Chunlei Yu; Zhennan Ye; Yan Luo; Lei Liu; Yan Li; Shile Huang
Journal:  Biochem Pharmacol       Date:  2016-07-07       Impact factor: 5.858

4.  A Candida albicans petite mutant strain with uncoupled oxidative phosphorylation overexpresses MDR1 and has diminished susceptibility to fluconazole and voriconazole.

Authors:  Shaoji Cheng; Cornelius J Clancy; Katherine T Nguyen; William Clapp; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2007-02-26       Impact factor: 5.191

Review 5.  Candida albicans cell wall proteins.

Authors:  W LaJean Chaffin
Journal:  Microbiol Mol Biol Rev       Date:  2008-09       Impact factor: 11.056

6.  Vulvovaginal Candidosis (excluding chronic mucocutaneous candidosis). Guideline of the German Society of Gynecology and Obstetrics (AWMF Registry No. 015/072, S2k Level, December 2013).

Authors:  W Mendling; K Friese; I Mylonas; E-R Weissenbacher; J Brasch; M Schaller; P Mayser; I Effendy; G Ginter-Hanselmayer; H Hof; O Cornely; M Ruhnke
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-04       Impact factor: 2.915

Review 7.  Repositioning the Old Fungicide Ciclopirox for New Medical Uses.

Authors:  Tao Shen; Shile Huang
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

8.  Potential of Ergosterol synthesis inhibitors to cause resistance or cross-resistance in Trichophyton rubrum.

Authors:  Emilia Ghelardi; Francesco Celandroni; Sokhna Aissatou Gueye; Sara Salvetti; Sonia Senesi; Anna Bulgheroni; Federico Mailland
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

9.  The innate growth bistability and fitness landscapes of antibiotic-resistant bacteria.

Authors:  J Barrett Deris; Minsu Kim; Zhongge Zhang; Hiroyuki Okano; Rutger Hermsen; Alexander Groisman; Terence Hwa
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

10.  Modes of action of the new arylguanidine abafungin beyond interference with ergosterol biosynthesis and in vitro activity against medically important fungi.

Authors:  C Borelli; M Schaller; M Niewerth; K Nocker; B Baasner; D Berg; R Tiemann; K Tietjen; B Fugmann; S Lang-Fugmann; H C Korting
Journal:  Chemotherapy       Date:  2008-06-30       Impact factor: 2.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.